DNAC News and Press, Social Capital Suvretta Holdings Corp. III

Social Capital Suvretta Holdings Corp. III (“SCS”) today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney LP, a limited partn...

SPAC Social Capital Suvretta Holdings Corp. III ( NASDAQ: DNAC ) said in a filing that it has delayed the shareholder vote to approve its planned merger with biotech company ProKidney to allow for extra time for certain closing conditions to be met. SCS said in an 8-K fili...

Gainers: The Marygold Companies ( MGLD ) +10% . Social Capital Suvretta Holdings ( DNAC ) +6% . Rocket Companies ( RKT ) +5% . Losers: Oxbridge Re Holdings ( OXBR ) -14% . Noah Holdings ( NOAH ) -11% . KE Holdings ( BEKE ) -11% ....

Gainers: Cowen ( COWN ) +25%, Symbotic ( SYM ) +20%, Grab ( GRAB ) +13%, Cipher Mining ( CIFR ) +12%, Zhong Yang Financial ( TOP ) +11% . Losers: Social Capital Suvretta III ( DNAC ) -15%, Pintec Technology ( PT ) -14%,...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today publi...

WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced an update on manufacturing efficiency and supply cha...

Potential for Amplified Therapeutic Effect of REACT ™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 WINSTON-SALEM, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading cli...

WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announce...